The business model consists in the licensing of IP Rights to a Bio-tech company in exchange of Up-Front Fee and Royalties (expected 5%, may vary based on the invest timing of the deal). The licensee company will produce, and possibly distribute, the diagnostic kit able to reduce the costs.
Exosome-based Liquid Biopsy Products
SOL Bio Corporation is developing early diagnosis products for various cancers by employing our unique exosome isolation technology and on-site biosensor platform
Such efforts will build the brand of early cancer diagnosis products of our company in the global market
We have secured the pipeline of the diagnosis products to launch them in the major markets, for example, the U.S. government and domestic markets (more than 40 per cent of the global market)